Transthyretin Amyloidosis Treatment Market to Grow with a CAGR of 7.26% through 2028
Increasing prevalence of
transthyretin amyloidosis are expected to drive the Global Transthyretin
Amyloidosis Treatment Market growth in the forecast period, 2024-2028.
According to
TechSci Research report, “Transthyretin Amyloidosis Treatment Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities,
2028”, the Global Transthyretin Amyloidosis Treatment Market stood at USD
4.95 Billion in 2022 and is anticipated to grow with a CAGR of 7.26% through
2028. The COVID-19 pandemic negatively impacted the market growth owing to the
decrease in a clinical trials for the drugs that could be used for the
transthyretin amyloidosis treatment. For instance, in September 2020, an
article published in the NCBI stated that a 74% of reduction has been witnessed
in the average number of patients entering clinical trials. Patients suffering
from transthyretin amyloidosis have a higher risk of mortality and morbidity
owing to their age and ATTR- amyloidosis-related organ dysfunction. Therefore,
proper characterization of risk and management implications are needed for the
patients if they develop COVID-19. The implications of delayed diagnosis and
interrupting treatment of patients should be balanced considering the risk of
exposure to the virus in the healthcare setting. The increasing prevalence of
transthyretin amyloidosis is anticipated to fuel market growth. Based on the
article published on Prothena, it is estimated that around 50,000 people live
with hATTR amyloidosis and about 400,000 people live with ATTRwt amyloidosis
worldwide. The growing geriatric population in the country is anticipated to
increase the prevalence of transthyretin amyloidosis over the forecast period.
As per the NCBI data, an age-related form of amyloidosis primarily affects the
heart and is also known as wild-type ATTR. For instance, in 2020, around 727
million people globally were aged 65 years and above. The geriatric population
worldwide is growing substantially at a rate of 16.0% and is expected to reach
1.5 billion in 2050. Aging is considered a substantial risk factor for wild
types of amyloidosis (ATTRwt).
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Transthyretin Amyloidosis Treatment Market”
The Global Transthyretin
Amyloidosis Treatment Market is segmented into Type, Therapy ,Disease Type, Distribution
Channel, and company.
Based on the
Disease Type, the Hereditary transthyretin amyloidosis segment is anticipated
to witness substantial market growth throughout the forecast period. The Global
Transthyretin Amyloidosis Treatment Market is poised for significant growth,
driven by the prevalence and recognition of hereditary transthyretin
amyloidosis (hATTR). As genetic testing and diagnostic capabilities advance,
there is a heightened awareness of hATTR, contributing to an expanding patient
pool seeking treatment interventions. The distinct genetic basis of hATTR not
only underscores the need for specialized therapies but also propels research
and development efforts to address the unique challenges posed by hereditary
forms of the disease. Pharmaceutical companies, recognizing the specific
demands of hATTR, are investing in targeted therapeutic solutions tailored to
the genetic underpinnings of the condition. This strategic focus on hereditary
transthyretin amyloidosis not only ensures more effective treatments but also
positions companies competitively in an evolving market landscape. Moreover,
the genetic heritability of the disease emphasizes the importance of early
intervention and proactive management, creating a sustained demand for
treatment options.
Based on the
Distribution Channel segment, the Hospital Pharmacies segment has been the
dominant force in the market. The growth of the Global Transthyretin
Amyloidosis Treatment Market is intricately linked to the pivotal role played
by hospital pharmacies. As frontline healthcare providers, hospital pharmacies
serve as crucial distribution hubs for specialized transthyretin amyloidosis
treatments. The increasing prevalence of the condition, coupled with the demand
for timely and effective interventions, positions hospital pharmacies as key
contributors to market expansion. Hospital pharmacies play a central role in
the continuum of care, ensuring the availability and accessibility of
transthyretin amyloidosis treatments to patients within the healthcare facility.
Their strategic location within hospitals streamlines the prescription
fulfillment process, facilitating efficient and coordinated patient care.
Moreover, hospital pharmacies often collaborate closely with healthcare
professionals, enabling them to provide valuable insights into treatment
options and patient adherence. This collaboration fosters a seamless
integration of transthyretin amyloidosis therapies into comprehensive patient
care plans.
Major companies
operating in Global Transthyretin Amyloidosis Treatment Market are:
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- Ionis Pharmaceuticals Inc.
- Alnylam Pharmaceuticals Inc.
- BridgeBio Pharma Inc.
- Bristol-Myers Squibb Company.
- Acrotech Biopharma.
- AstraZeneca Plc.
- SOM Biotech.
Download Free Sample Report
Customers can
also request 10% free customization on this report
“The increasing
prevalence of transthyretin amyloidosis, Initiatives undertaken by government
and non-government bodies for creating awareness regarding the disease and its treatment
benefits among people are expected to boost early diagnosis of disease, thereby
increasing the treatment rate. Increasing novel
drugs prescription, proper reimbursement policies, and higher treatment rates
in the region are factors supporting transthyretin amyloidosis treatment market
growth in the region. Moreover, major
factors such as a large target population, good healthcare reforms, and an
increase in disease awareness are expected to be the primary growth factors. Several market players are working toward the
development and commercialization of drugs for the proper diagnosis and
treatment of transthyretin amyloidosis.” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Transthyretin
Amyloidosis Treatment Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028 Segmented By Type (ATTR-PN, ATTR-CM), By
Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive
Therapy, Pipeline Therapy), By Disease Type (Hereditary Transthyretin
Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type
Amyloidosis), By Distribution Channel (Hospital Pharmacies, Specialty
Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, By Competition”,
has evaluated the future growth potential of Global Transthyretin Amyloidosis
Treatment Market and provides statistics
& information on market size, structure and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Transthyretin Amyloidosis Treatment Market.
Contact
TechSci Research
LLC
420 Lexington
Avenue, Suite 300,
New York, United
States- 10170
Tel:
+1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com